SCHEMBL884480

SCHEMBL884480

CN(C)CCNC(=O)c1cccc(-c2ccccc2CC(c2cccnc2)c2cccnc2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 6/20 0.71
KCNH2 Q12809 4/20 0.57
CAMK2D Q13557 1/20 0.48
FYN P06241 2/20 0.46
EGFR P00533 1/20 0.46
EPHX2 P34913 2/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
WNT1 P04628 1/20 0.45
DYRK1A Q13627 1/20 0.45
PARP1 P09874 2/20 0.44
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM5 P08912 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
RAD52 P43351 2/20 0.44
PRKD3 O94806 1/20 0.44
PRKD1 Q15139 1/20 0.44
PRKD2 Q9BZL6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL884297 0.89 KCNA5 (0.67) KCNA5KCNH2FYNEPHX2CYP2C9
SCHEMBL2063300 0.86 KCNA5 (0.67) KCNA5KCNH2EPHX2CYP2C9CYP2C19
SCHEMBL885046 0.85 KCNA5 (0.67) KCNA5KCNH2EPHX2CYP2C9CYP2C19
SCHEMBL884585 0.84 KCNA5 (0.66) KCNA5KCNH2CYP2C9CYP2C19
SCHEMBL884680 0.84 KCNA5 (0.61) KCNA5KCNH2EPHX2CYP2C9CYP2C19
SCHEMBL884608 0.83 KCNA5 (1.00) KCNA5KCNH2
SCHEMBL884694 0.83 KCNA5 (0.65) KCNA5KCNH2EPHX2DYRK1A
SCHEMBL884716 0.83 KCNA5 (0.65) KCNA5KCNH2EPHX2CYP2C9CYP2C19
SCHEMBL17154227 0.82 FYN (0.49) KCNA5CAMK2DFYNEGFRPARP1
SCHEMBL884527 0.82 KCNA5 (0.66) KCNA5KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US claimed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP claimed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO claimed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885CAMK2D 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.